Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.

Mathur W, Kosta S, Reddy M, Neto MG, Bhandari M

Obesity surgery13 Dec 2023Cited by 4 (Europe PMC)

PMID38091192DOI10.1007/s11695-023-06975-8PepBankPUB-38091192

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, adding oral semaglutide gave a total weight loss of 7.9% versus 6.1% without it at 1 month.
In plain wordsIn adults with obesity with a swallow balloon, adding oral semaglutide gave 7.9% weight loss at 1 month, compared with 6.1% without it.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss at 1 month
Study
n = 115
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
Total weight loss
7.9%
group I, month 1
Total weight loss
6.1%
group II, month 1
Source sentences
Summary
The %TWL in group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, and 13.7% at 1, 2, 3, and 4 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119201
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, adding oral semaglutide gave a total weight loss of 12.5% versus 10.5% without it at 2 months.
In plain wordsIn adults with obesity with a swallow balloon, adding oral semaglutide gave 12.5% weight loss at 2 months, compared with 10.5% without it.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss at 2 months
Study
n = 115
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
Total weight loss
12.5%
group I, month 2
Total weight loss
10.5%
group II, month 2
Source sentences
Summary
The %TWL in group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, and 13.7% at 1, 2, 3, and 4 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119202
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, adding oral semaglutide gave a total weight loss of 15.2% versus 12.8% without it at 3 months.
In plain wordsIn adults with obesity with a swallow balloon, adding oral semaglutide gave 15.2% weight loss at 3 months, compared with 12.8% without it.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss at 3 months
Study
n = 115
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
Total weight loss
15.2%
group I, month 3
Total weight loss
12.8%
group II, month 3
Source sentences
Summary
The %TWL in group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, and 13.7% at 1, 2, 3, and 4 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119203
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, adding oral semaglutide gave a total weight loss of 17.6% versus 13.7% without it at 4 months.
In plain wordsIn adults with obesity with a swallow balloon, adding oral semaglutide gave 17.6% weight loss at 4 months, compared with 13.7% without it.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss at 4 months
Study
n = 115
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
Total weight loss
17.6%
group I, month 4
Total weight loss
13.7%
group II, month 4
Source sentences
Summary
The %TWL in group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, and 13.7% at 1, 2, 3, and 4 months, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119204
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, type 2 diabetes resolved in 64.7% with semaglutide versus 55.5% without it; no test is reported.
In plain wordsIn adults with obesity with a swallow balloon, diabetes resolved in 64.7% with semaglutide and 55.5% without it. No statistical test was reported.
Peptide
Semaglutide
Outcome
IncreaseResolution of type 2 diabetes
Study
n: not reported in source
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
T2DM resolution
64.7%
group I
T2DM resolution
55.5%
group II
Source sentences
Summary
The resolution of T2DM, HTN, and OSA was 64.7% vs 55.5%
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119205
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, hypertension resolved in 64.3% with semaglutide versus 58.8% without it; no test is reported.
In plain wordsIn adults with obesity with a swallow balloon, high blood pressure resolved in 64.3% with semaglutide and 58.8% without it. No statistical test was reported.
Peptide
Semaglutide
Outcome
IncreaseResolution of hypertension
Study
n: not reported in source
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Blood pressure · Cardiovascular
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
HTN resolution
64.3%
group I
HTN resolution
58.8%
group II
Source sentences
Summary
The resolution of T2DM, HTN, and OSA was 64.7% vs 55.5%, 64.3% vs 58.8%, and 72.0 vs 57.8% in groups I vs II, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119206
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity with a swallow balloon, obstructive sleep apnoea resolved in 72.0% with semaglutide versus 57.8% without it; no test is reported.
In plain wordsIn adults with obesity with a swallow balloon, sleep apnoea resolved in 72.0% with semaglutide and 57.8% without it. No statistical test was reported.
Peptide
Semaglutide
Outcome
IncreaseResolution of obstructive sleep apnoea
Study
n: not reported in source
Comparator
Swallow balloon without semaglutide (group II)
Outcome group
Sleep · Respiratory
Studied dose
3 mg once daily (month 1), 7 mg (month 2), 14 mg (months 3-4) · oral · 4 monthsAs given in this study (human).
Measurements
OSA resolution
72%
group I
OSA resolution
57.8%
group II
Source sentences
Summary
The resolution of T2DM, HTN, and OSA was 64.7% vs 55.5%, 64.3% vs 58.8%, and 72.0 vs 57.8% in groups I vs II, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
Report a problemFND-3809119207

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

08HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome
In adults with obesity treated with a swallow balloon, with or without oral semaglutide, nausea and vomiting were the most common adverse events, seen within the first week.
In plain wordsIn adults with obesity with a swallow balloon, nausea and vomiting were the most common side effects, within the first week.
Peptide
Semaglutide
Outcome
Not applicableMost common adverse events
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
The most common adverse events (AEs) were nausea and vomiting, observed within the week.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3809119208
09HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity treated with a swallow balloon, with or without oral semaglutide, quality of life improved significantly at 4 months in both groups.
In plain wordsIn adults with obesity with a swallow balloon, quality of life improved in both groups, with or without semaglutide.
Peptide
Semaglutide
Outcome
IncreaseQuality of life at 4 months
Study
n: not reported in source
Comparator
Baseline
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
QoL significantly improved 4 months postoperatively in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3809119209
10HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome
In adults with obesity treated with a swallow balloon, with or without oral semaglutide, no major late complications occurred in either group.
In plain wordsIn adults with obesity with a swallow balloon, no major late complications occurred in either group.
Peptide
Semaglutide
Outcome
No significant changeMajor late complications
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
No major late complications occurred in either of the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven participants were assigned to swallow balloon therapy group I (with semaglutide), and 58 were assigned to swallow balloon therapy group II (without semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3809119210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.